EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel CIP2A and BCL-XL Clinical Diagnostic Toolkit to Predict Disease Progression and Treatment-Free Remission in Chronic Myeloid Leukaemia

Ammar A Basabrain iD, Gemma M Austin, Alison K Holcroft, Jane F Apperley, Richard E Clark, Shankar Varadarajan, Claire M Lucas iD

International Journal of Molecular Sciences · 25.03.2026 · 27 (7) · 2991

DOI: 10.3390/ijms27072991 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.03.2026. Verfasst von Ammar A Basabrain und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia. Hauptthemen laut MEDLINE: bcl-X Protein, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Intracellular Signaling Peptides and Proteins, Membrane Proteins. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah, University of Chester QR, University of Chester QR https://ror.org/01drpwb22.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biomarkers that predict disease progression and treatment-free remission (TFR) would be of significant clinical value in chronic myeloid leukaemia (CML). We have previously shown that CIP2A levels at diagnosis can identify patients at increased risk of progression. One mechanism by which CIP2A acts is through upregulation of the anti-apoptotic gene BCL-XL. In this study, we evaluated BCL-XL mRNA expression as a diagnostic biomarker using samples from the SPIRIT2 and DESTINY clinical trials. In SPIRIT2, which compared imatinib and dasatinib as first-line therapies, high BCL-XL expression was associated with treatment failure, poor early molecular response, and lower rates of MR2 and MR3 achievement in patients treated with imatinib. In the DESTINY trial, which assessed treatment de-escalation and discontinuation, BCL-XL expression was significantly higher in patients who experienced molecular relapse compared to those achieving sustained TFR. Notably, increases in BCL-XL were detectable 6 to 8 months prior to molecular relapse, suggesting it may serve as an early biomarker of unsuccessful TFR. We now propose a clinical diagnostic toolkit combining CIP2A and BCL-XL biomarkers to stratify CML patients by the risk of disease progression and likelihood of achieving successful TFR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

bcl-X ProteinLeukemia, Myelogenous, Chronic, BCR-ABL PositiveIntracellular Signaling Peptides and ProteinsMembrane ProteinsAutoantigensBiomarkers, TumorHumansDisease ProgressionDasatinibImatinib MesylateRemission InductionPrognosis

Stichwörter der Autor:innen

BCL-XLBCR::ABL1CIP2ACMLDESTINYMR2 and MR3)SPIRIT2biomarkerclinical trialdasatinibimatinibmolecular responses (EMRtreatment failuretreatment-free remission (TFR)

Substanzen

bcl-X ProteinIntracellular Signaling Peptides and ProteinsMembrane ProteinsCIP2A protein, humanAutoantigensBiomarkers, TumorBCL2L1 protein, humanDasatinibImatinib Mesylate

Autor:innen und Institutionen

  • Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  • Hematology Research Unit, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  • Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, UK.
  • Centre for Haematology, Imperial College London at Hammersmith Hospital, London W12 0HS, UK.
  • Chester Centre for Leukaemia Research, Chester Medical School, University of Chester, Bache Hall, Chester CH2 1BR, UK.

ORCID-Profile: Ammar A Basabrain, Claire M Lucas

Förderung

  • The Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah
  • University of Chester QR
  • University of Chester QR https://ror.org/01drpwb22

Zitieren

APA

Basabrain, A. A., Austin, G. M., Holcroft, A. K., Apperley, J. F., Clark, R. E., Varadarajan, S., & Lucas, C. M. (2026). A Novel CIP2A and BCL-XL Clinical Diagnostic Toolkit to Predict Disease Progression and Treatment-Free Remission in Chronic Myeloid Leukaemia. International Journal of Molecular Sciences, 27(7), 2991. https://doi.org/10.3390/ijms27072991

Vancouver

Basabrain AA, Austin GM, Holcroft AK, Apperley JF, Clark RE, Varadarajan S, et al. A Novel CIP2A and BCL-XL Clinical Diagnostic Toolkit to Predict Disease Progression and Treatment-Free Remission in Chronic Myeloid Leukaemia. International Journal of Molecular Sciences. 2026;27(7):2991. doi:10.3390/ijms27072991

BibTeX
@article{Basabrain2026,
  author = {Basabrain, Ammar A and Austin, Gemma M and Holcroft, Alison K and Apperley, Jane F and Clark, Richard E and Varadarajan, Shankar and Lucas, Claire M},
  title = {A Novel CIP2A and BCL-XL Clinical Diagnostic Toolkit to Predict Disease Progression and Treatment-Free Remission in Chronic Myeloid Leukaemia},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {7},
  pages = {2991},
  doi = {10.3390/ijms27072991}
}
Kostenlos starten →